1. In this cross-sectional study, distance to the nearest lung cancer screening facility was greater in American Indian/Alaska Native-majority census...
1. Median event-free survival was 54.8 months with immunotherapy vs 20.9 months with chemotherapy, with HR 0.77 (non-significant). 2. Grade...
1. Local progression-free survival at 3 years was 84.3% in the SBRT group vs 67.3% in the RFA group, with...
1. Pembrolizumab plus radiotherapy and surgery significantly improved disease-free survival. 2. Grade 3 or higher adverse events were more common...
1. Progression-free survival improved significantly in patients with low-volume disease who received abiraterone and radiotherapy. 2. The addition of radiotherapy...
1. The large language model, ChatGPT-4, answered 85.0% of examination-style multiple-choice questions on medical oncology correctly, a performance superior to...
1. Median progression-free survival was 9.4 months in the imlunestrant–abemaciclib group vs 5.5 months in the imlunestrant group with HR...
1. In this randomized controlled trial, among patients with early-stage triple-negative breast cancer (TNBC), the addition of neoadjuvant and adjuvant...
1. In this randomized controlled trial, two cycles of neoadjuvant ipilimumab plus nivolumab resulted in longer event-free survival than adjuvant...
1. In this randomized controlled trial, in patients with PIK3CA-mutated advanced breast cancer, the addition of inavolisib to a palbociclib-fulvestrant...
